RTI Biologics Inc. : RTI Biologics Schedules 2012 Fourth Quarter, Year End Earnings and Conference Call For February 7

01/31/2013

• Jenny Highlander, APR
• Manager of Corporate Communications & External Relations
• [e-mail]

• Robert Jordheim
• Chief Financial Officer
• [e-mail]

ALACHUA, Fla. (Jan. 31, 2013) - RTIBiologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, announced today that it plans to release financial results from the fourth quarter and year end 2012 on Thursday, Feb. 7, 2013 prior to the market open.

RTIwill host a conference call and simultaneous audio webcast to discuss the fourth quarter and year end 2012 results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing [phone]. The webcast can be accessed through the investor section of RTI's website at www.rtix.com. A replay of the conference call will be available on the RTIwebsite for one month following the call.

About RTIBiologics Inc.

RTIBiologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTIprepares human donated tissue and animal tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI's innovations continuously raise the bar of science and safety for biologics - from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. The BioCleanse® Tissue Sterilization Process, the Tutoplast® Tissue Sterilization Process and the Cancelle™ SP Demineralization Process have a combined record of more than four million implants distributed with zero incidence of implant-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

###